ICU MEDICAL INC/DE·4

Mar 9, 4:32 PM ET

Bonnell Brian Michael 4

Research Summary

AI-generated summary

Updated

ICU Medical CFO Brian Bonnell Receives 75,279 Shares, Sells 39,667

What Happened

Brian Michael Bonnell, Chief Financial Officer of ICU Medical (ICUI), acquired a total of 75,279 shares through the settlement/conversion of restricted stock units and performance-based RSUs (3,522 shares on 2026-03-07 and 71,757 shares on 2026-03-08). Following the vesting/settlement, he disposed of shares to satisfy tax withholding: 1,263 shares (3/7) and 39,667 shares (3/8) — the latter sold at $132.00 per share for proceeds of $5,236,044. The acquisitions resulted from PRSUs that were earned at 250% of target after performance certification.

Key Details

  • Transaction dates: 2026-03-07 and 2026-03-08 (filed 2026-03-09 — timely filing).
  • Acquisitions: 3,522 shares (3/7) and 71,757 shares (3/8) — total 75,279 shares acquired via conversion/settlement (derivative code M).
  • Disposals for tax withholding: 1,263 shares (3/7, $0 reported) and 39,667 shares (3/8 at $132.00) — 39,667 shares generated $5,236,044 (disposition code F).
  • Footnotes: Shares are Restricted Stock Units and Performance-based RSUs (PRSU). PRSUs granted 3/8/2024 were certified 2/11/2026 and paid at 250% of target. RSUs/PRSUs have no purchase/exercise price. Vesting schedules noted in footnotes (one-third annual vesting or full vest at 3 years, as applicable).
  • Shares owned after the transactions: not specified in the filing.

Context

  • Codes: M = conversion/exercise of derivative (here, settlement of RSUs/PRSUs into shares); F = shares used to pay exercise price or tax liability (here, tax withholding). The sale of 39,667 shares was to cover tax obligations rather than an open-market investment decision.
  • These transactions reflect routine post-vesting tax withholding following the settlement of performance and restricted stock awards; they do not necessarily indicate additional buying or selling for investment purposes.